| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 316.1 | 207.0 | 242.4 |
| Other income | 1.3 | 1.7 | 1.4 |
| Total income | 317.4 | 208.7 | 243.9 |
| Profit before exceptional items & tax | 52.8 | 27.2 | 34.0 |
| Profit before tax | 52.8 | 27.2 | 34.0 |
| Net profit | 39.9 | 20.9 | 25.3 |
| Operating margin | 16.6% | 13.0% | 13.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +57.70% |
|---|---|
| Net profit, quarter on quarter | +90.90% |
| Revenue, year on year | +30.40% |
| Operating profit, year on year | +58.00% |
| Operating profit, quarter on quarter | +102.00% |
NSE results filing, NSE: SMSPHARMA. Figures extracted from the filing.
SMS Pharmaceuticals Ltd: key numbers
- Share price
- ₹524.90
- Market cap
- ₹4,653 Cr
- Revenue (annual)
- ₹886.9 Cr
- Net profit (annual)
- ₹102.0 Cr
- P/E (TTM)
- 45.4×Sector 41.3×
- Promoter holding
- 68.07%+0.00% QoQ
- FII holding
- 1.18%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from SMS Pharmaceuticals Ltd
All →SMS Pharmaceuticals Results Update
SMS Pharmaceuticals released a press release on its Q2 and H1 FY27 results, showing strong growth. Management now expects FY27 revenue growth and EBITDA margins above earlier guidance.
SMS Pharmaceuticals Investor Presentation: Key Takeaways
Q2FY27 revenue ₹316 Cr (+30% YoY), EBITDA ₹68 Cr at 21% margin, PAT ₹40 Cr (+57%). Strategy: backward integration, high-value APIs, DMF/CEP filings, ₹280 Cr capex.
SMS Pharmaceuticals Management Change
SMS Pharmaceuticals' Company Secretary Thirumalesh Tumma resigned effective November 4, 2026. Manohar Mollama has been appointed as the new Company Secretary effective November 5, 2026.
SMS Pharmaceuticals Legal & Regulatory
SMS Pharmaceuticals received an Income Tax appellate order under Section 250 dismissing its appeal for AY 2018-19. The company says there is no material impact and is reviewing next steps.
- Value
- ₹0.40 Cr
SMS Pharmaceuticals Legal & Regulatory
SMS Pharmaceuticals disclosed that the CIT(Appeals) dismissed its appeal against a ₹7.19 Crore income tax assessment for AY 2018-19. The company is reviewing the order and expects no material impact.
- Value
- ₹7.19 Cr
SMS Pharmaceuticals Legal & Regulatory
SMS Pharmaceuticals received an Income Tax appellate order allowing its appeal for AY 2023-24. The outstanding tax demand of Rs.45.63 Crore, including interest, stands vacated.
- Value
- ₹45.63 Cr